Crossmark

Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?

Published Online: 2021-01-06

Published Print: 2021-02

Authors

Othman, Tamer

Herrera, Alex

Mei, Matthew http://orcid.org/0000-0002-1109-6955
License Information

Text and Data Mining valid from 2021-01-06

Version of Record valid from 2021-01-06
More Information

Article History

Accepted: 29 December 2020

First Online: 6 January 2021

Compliance with Ethical Standards

:

: Tamer Othman declares no potential conflicts of interest.Alex Herrera—Consulting or Advisory Role, Bristol-Myers Squibb; Merck; Seattle Genetics; Karyopharm, Research Funding, Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Seattle Genetics (Inst); ADC Therapeutics (Inst); Kite Pharma/Gilead (Inst), Travel, Accommodations, Expenses, Bristol-Myers SquibbMatthew Mei—Consulting or Advisory Role, Morphosys; Sanofi Genzyme

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Document is current